0001209191-23-026069.txt : 20230428
0001209191-23-026069.hdr.sgml : 20230428
20230428165451
ACCESSION NUMBER: 0001209191-23-026069
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230426
FILED AS OF DATE: 20230428
DATE AS OF CHANGE: 20230428
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CLARKE JOHN K
CENTRAL INDEX KEY: 0001219015
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37378
FILM NUMBER: 23867734
MAIL ADDRESS:
STREET 1: C/O CARDINAL HEALTH PARTNERS
STREET 2: 221 NASSAU STREET
CITY: PRINCETON
STATE: NJ
ZIP: 08542
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: aTYR PHARMA INC
CENTRAL INDEX KEY: 0001339970
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 203435077
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10240 SORRENTO VALLEY ROAD
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 8587318389
MAIL ADDRESS:
STREET 1: 10240 SORRENTO VALLEY ROAD
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-04-26
0
0001339970
aTYR PHARMA INC
LIFE
0001219015
CLARKE JOHN K
C/O ATYR PHARMA, INC.
10240 SORRENTO VALLEY ROAD, SUITE 300
SAN DIEGO
CA
92121
1
0
0
0
0
Common Stock
2023-04-26
4
M
0
6000
A
19797
D
Restricted Stock Unit
2023-04-26
4
M
0
6000
0.00
D
Common Stock
0
0
D
Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on April 26, 2022.
RSUs convert into common stock on a one-for-one basis.
Includes 6,305 shares received as a pro-rata distribution on September 28, 2021 (the "Liquidating Distribution") from CHP II, L.P., in which the Reporting Person is a managing partner. In prior reports, the reporting person reported beneficial ownership of 108,083 shares of aTyr Pharma common stock held by CHP II, L.P., which are no longer held as of September 28, 2021 due to the Liquidating Distribution.
The RSUs fully vested one year from the grant date which was April 26, 2022.
Nancy E. Denyes, Attorney-In-Fact
2023-04-28